The Technical Analyst
Select Language :
Biofrontera AG [BFRA]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Biofrontera AG Price, Forecast, Insider, Ratings, Fundamentals & Signals

Biofrontera AG is listed at the  Exchange

-2.91% $2.67

America/New_York / 31 des 1970 @ 19:00


Biofrontera AG: Main Fundamentals PE comparison

RATING 2022-05-06
B-
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Strong Buy
Return On Asset: Neutral
DE: Strong Sell
P/E: Strong Sell
Price To Book: Strong Sell
QUARTER GROWTHS
2/203/204/201/212/213/21
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -4.35 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.74x
Company: PE -4.35 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 2.35 - 2.99

( +/- 12.13%)
ATR Model: 14 days

Forecast: 01:40 - $2.29

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $2.67 (-2.91% )
Volume 0.0050 mill
Avg. Vol. 0.0305 mill
% of Avg. Vol 16.22 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Biofrontera AG

Last 12 Months

Last 12 months chart data with high, low, open and close for Biofrontera AG

RSI

Intraday RSI14 chart for Biofrontera AG

Last 10 Buy & Sell Signals For BFRA

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Biofrontera AG

BFRA

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

Last 10 Buy Signals

Date Signal @
RIOUSDMar 29 - 10:192.44
DAIUSDMar 29 - 10:16$0.999
FLIPUSDMar 29 - 10:055.04
SCNSOLUSDMar 29 - 09:59220.06
INVUSDMar 29 - 09:5963.18
SUPERUSDMar 29 - 09:34$1.359
UQCUSDMar 29 - 06:54$7.20
BNBUSDMar 29 - 09:31$615.19
TIMEUSDMar 29 - 09:3232.37
AGLDUSDMar 29 - 09:301.650

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.